[{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"SEL120","moa":"CDK8","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"POLAND","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Galapagos NV","highestDevelopmentStatusID":"2","companyTruncated":"Ryvu Therapeutics \/ Galapagos NV"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"MEN1703","moa":"PIM","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"National Centre for Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"SEL120","moa":"CDK8","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ National Centre for Research and Development","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Therapeutics \/ National Centre for Research and Development"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"MEN1703","moa":"PIM","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Menarini Group","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Menarini Group"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"RVU120","moa":"CDK8\/9","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"RVU120","moa":"CDK8\/9","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"MEN1703","moa":"PIM","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"RVU120","moa":"CDK8\/9","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Menarini","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"MEN1703","moa":"PIM","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Ryvu Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Ryvu Therapeutics"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"RVU120","moa":"CDK8\/9","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-Drug Conjugate Based Therapeutic","moa":"STING","graph1":"Oncology","graph2":"Discovery","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Ryvu Therapeutics \/ Exelixis"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"RVU120","moa":"CDK8\/CDK19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"RVU120","moa":"CDK8\/CDK19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"RVU120","moa":"CDK8\/CDK19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ryvu Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ BioNTech","highestDevelopmentStatusID":"2","companyTruncated":"Ryvu Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"RVU120","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"MEN1703","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Menarini","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"RVU120","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Polpharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"RVU120","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Ryvu Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ryvu Therapeutics \/ Ryvu Therapeutics"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RVU120","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RVU120","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RVU120","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"nCage Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ nCage Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Ryvu Therapeutics \/ nCage Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals by Ryvu Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
